Pharmacy benefit managers and health carriers usage of prescription drug rebates and other compensation requirement to benefit covered persons provision
Summary
SF 1877 would require pharmacy benefit managers (PBMs) and health carriers to use compensation they receive from drug manufacturers—such as rebates, discounts, fees, credits, chargebacks, and similar payments—to directly reduce a covered person’s out-of-pocket cost for a prescription drug at the point of sale. In general, the bill directs that all such compensation tied to a particular prescription be passed through to the patient, unless the patient’s cost-sharing amount is already lower than what it would be after applying the compensation.
If a PBM or health carrier retains any compensation under that exception, the retained amount must be used in plan design to offset future premiums or other costs for covered persons. The bill also requires annual compliance reports to the commissioner beginning March 1, 2026, and it specifically requires state employee group insurance program contracts to include compliance with these requirements. The new section would be added to Minnesota Statutes, chapter 62W, and would take effect January 1, 2026.
Impact
The bill would create a new statutory requirement in Minnesota law governing how PBMs and health carriers handle manufacturer compensation associated with prescription drug benefits. It would effectively mandate point-of-sale pass-through of rebates and similar payments to lower patient cost-sharing, with a limited exception for low-cost prescriptions, and it would impose reporting obligations to the state regulator. The measure would also affect state employee health coverage contracts by requiring those contracts to incorporate compliance with the new rule.
Sentiment
The available record shows no committee transcript or recorded votes, so there is no direct evidence of debate, amendments, or partisan division in the materials provided. Based on the bill’s structure, the measure appears aimed at lowering prescription drug costs for consumers, suggesting a consumer-protection and affordability rationale. Because no discussion or vote history is included, the overall sentiment can only be characterized as neutral-to-supportive on the face of the bill, with no documented opposition in the supplied context.
Contention
The main policy tension in the bill is how to balance immediate patient savings against PBM and insurer flexibility in plan design. Supporters would likely favor requiring rebates and other compensation to reduce out-of-pocket costs at the pharmacy counter, while potential opponents may argue that mandatory pass-through could affect premium levels, contracting practices, or administrative complexity. The bill’s exception for prescriptions with relatively low cost-sharing, and its requirement that retained compensation be used to offset future premiums or costs, suggest an attempt to address those concerns, but no specific stakeholder objections are documented in the provided materials.
Similar To
Pharmacy benefit managers and health carriers required to use prescription drug rebates and other compensation to benefit covered persons, and report required.
Pharmacy benefit managers and health carriers required to use prescription drug rebates and other compensation to benefit covered persons, and report required.
Pharmacy benefit managers and health carriers inclusion of lower-cost drugs in formularies requirement provision and lowest out-of-pocket-cost drug to patient formulary tiering preference provision